Nivolumab was subsequently approved for second-line treatment of advanced non-squamous NSCLC in the US (October 2015) and the European Union (April 2016) regardless of PD-L1 expression conferring improved efficacy compared to docetaxel. This evidence concerns the gene CD274 and non-small cell lung carcinoma.